Ocular Therapeutix, Inc. (OCUL) Stock Price, News, Quote & History - Yahoo Finance (2025)

Table of Contents

Full Time Employees Fiscal Year Ends Sector Industry Recent News: OCUL Performance Overview: OCUL YTD Return 1-Year Return 3-Year Return 5-Year Return Compare To: OCUL Statistics: OCUL Valuation Measures Financial Highlights Research Analysis: OCUL People Also Watch

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(Wt)}else s.style.display="block"},h=function(){d.refreshPanel().then(m).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(h(),setInterval((function(){h()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var f=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(to=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===f&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Jt)),notifLabel:document.querySelector(".".concat(Vt))};io(e,n)}))}()}};

NasdaqGM - Delayed Quote • USD

Compare

9.89 -0.17 (-1.69%)

At close: November 29 at 1:00 PM EST

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for OCUL

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

Previous Close 10.06
Open 10.08
Bid 9.87 x 200
Ask 9.92 x 100
Day's Range 9.74 - 10.15
52 Week Range 2.88 - 11.77
Volume 774,556
Avg. Volume 1,155,825
Market Cap (intraday) 1.582B
Beta (5Y Monthly) 1.26
PE Ratio (TTM) --
EPS (TTM) -1.29
Earnings Date Nov 14, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 18.22

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

www.ocutx.com

267

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Ocular Therapeutix, Inc.

Recent News: OCUL

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

OCULOcular Therapeutix, Inc.

9.89

-1.69%

Mkt Cap 1.582B

Industry Biotechnology

EYPTEyePoint Pharmaceuticals, Inc.

8.85

-2.21%

Mkt Cap 604.021M

Industry Biotechnology

MREOMereo BioPharma Group plc

3.6050

+1.26%

Mkt Cap 559.301M

Industry Biotechnology

AXSMAxsome Therapeutics, Inc.

98.22

-1.44%

Mkt Cap 4.829B

Industry Biotechnology

CYTKCytokinetics, Incorporated

51.86

-0.69%

Mkt Cap 6.163B

Industry Biotechnology

VTYXVentyx Biosciences, Inc.

2.6800

+1.13%

Mkt Cap 189.505M

Industry Biotechnology

APGEApogee Therapeutics, Inc.

45.15

+1.01%

Mkt Cap 2.544B

Industry Biotechnology

CRVSCorvus Pharmaceuticals, Inc.

9.09

-3.50%

Mkt Cap 605.303M

Industry Biotechnology

TARSTarsus Pharmaceuticals, Inc.

52.45

+3.17%

Mkt Cap 2.005B

Industry Biotechnology

TGTXTG Therapeutics, Inc.

34.80

-0.57%

Mkt Cap 5.448B

Industry Biotechnology

APLSApellis Pharmaceuticals, Inc.

33.93

-0.62%

Mkt Cap 4.247B

Industry Biotechnology

Statistics: OCUL

Valuation Measures

As of 11/29/2024

Market Cap

1.55B
Enterprise Value

1.20B
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

22.34
Price/Book (mrq)

4.42
Enterprise Value/Revenue

19.58
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

-226.46%
Return on Assets (ttm)

-22.37%
Return on Equity (ttm)

-72.67%
Revenue (ttm)

61.1M
Net Income Avi to Common (ttm)

-138.36M
Diluted EPS (ttm)

-1.29

Balance Sheet and Cash Flow

Total Cash (mrq)

459.69M
Total Debt/Equity (mrq)

19.83%
Levered Free Cash Flow (ttm)

-55.72M

Research Analysis: OCUL

People Also Watch

KPTI Karyopharm Therapeutics Inc.

0.8451

-0.87%

MRNS Marinus Pharmaceuticals, Inc.

0.3246

-0.06%

OMER Omeros Corporation

11.35

-4.70%

ALDX Aldeyra Therapeutics, Inc.

4.9000

-0.81%

AFMD Affimed N.V.

2.8400

0.00%

TGTX TG Therapeutics, Inc.

34.80

-0.57%

PTCT PTC Therapeutics, Inc.

43.88

-2.73%

AUPH Aurinia Pharmaceuticals Inc.

8.86

+0.11%

MGNX MacroGenics, Inc.

3.5900

-1.37%

PTGX Protagonist Therapeutics, Inc.

43.80

-2.56%

RVNC Revance Therapeutics, Inc.

3.6100

-4.50%

SNDX Syndax Pharmaceuticals, Inc.

16.72

+1.27%

EYPT EyePoint Pharmaceuticals, Inc.

8.85

-2.21%

ITCI Intra-Cellular Therapies, Inc.

85.65

-1.09%

KURA Kura Oncology, Inc.

11.04

-1.16%

CLSD Clearside Biomedical, Inc.

1.0500

-1.87%